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Available online 7 November 2017The class Ia anti-arrhythmic drug ajmaline is used clinically to unmask latent type I ECG in Brugada syndrome
(BrS) patients, although its mode of action is poorly characterised.
Our aims were to identify ajmaline's mode of action in human induced pluripotent stem cell (hiPSC)-derived
cardiomyocytes (CMs), and establish a simple BrS hiPSC platform to test whether differences in ajmaline
response could be determined between BrS patients and controls.
Control hiPSCs were differentiated into spontaneously contracting cardiac clusters. It was found using multi
electrode array (MEA) that ajmaline treatment signiﬁcantly lengthened cluster activation-recovery interval.
Patch clamping of single CMs isolated from clusters revealed that ajmaline can block both INa and IKr.
Following generation of hiPSC lines from BrS patients (absent of pathogenic SCN5A sodium channel mutations),
analysis of hiPSC-CMs from patients and controls revealed that differentiation and action potential parameters
were similar. Comparison of cardiac clusters byMEA showed that ajmaline lengthened activation-recovery interval
consistently across all lines.
We conclude that ajmaline can block both depolarisation and repolarisation of hiPSC-CMs at the cellular level, but
that a more reﬁned integrated tissue model may be necessary to elicit differences in its effect between BrS
patients and controls.tial Duration; B
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Brugada syndrome (BrS) is a cardiac arrhythmic syndrome and can
cause ventricular ﬁbrillation (VF) and sudden cardiac death. BrS isr1, Brugada Type
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en access article underpredominantly characterised by right bundle branch block, elevated J-
point and coved ST segment of an electrocardiogram (ECG), with ﬁbril-
lation and premature ventricular contractions often originating from
the right ventricular outﬂow tract (RVOT) (Brugada and Brugada,
1992; Morita et al., 2003). Two speciﬁc hypotheses have been proposed
to account for the Brugada ECG pattern - the depolarisation hypothesis,
highlighting the importance of right ventricular activation delays, and
the repolarisation hypothesis, focusing on transmural differences in
action potential duration (Meregalli et al., 2005).
The class IA anti-arrhythmic drug ajmaline is used as a diagnostic
pharmacological challenge in suspected cases of BrS (Rolf et al., 2003),
however the mechanism of action is not fully established, and there
has long been debate about the precision of its diagnostic effect
(Brugada et al., 2003). Some studies in non-human or non-cardiac cell
lines have indicated that ajmaline inhibits various currents, including
INa, Ito or IKr (Bébarová et al., 2005; Kiesecker et al., 2004). Furthermore,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tern in 27% of atrioventricular nodal re-entrant tachycardia patients
and even in 5% of control individuals (Hasdemir et al., 2015). The
exact pathophysiological mechanism whereby ajmaline provokes the
BrS ECG phenotype is thus unclear.
It is clear that in some cases BrS can be hereditary, and in these cases
occurs predominantly due to loss-of-function mutations in the cardiac
sodium channel SCN5A (Mizusawa and Wilde, 2012). Mutations have
also been identiﬁed in sodium channel beta subunits and in other ion
channels such as the L-type Ca2+ channel, however these are rare
(Mizusawa and Wilde, 2012). There is a diversity of other associated
genes with rare variants of sometimes disputed contribution (Le
Scouarnec et al., 2015), as well as combinations of common variants
likely to be contributing as disease modiﬁers (Bezzina et al., 2013). In
total, a monogenic aetiology can be reasonably supported in only
~25% of patients (Wilde and Behr, 2013). Thus in the majority of pa-
tients there is scant data supporting a strong genetic predisposition.
Furthermore, in addition to electrophysiological effects at the single
cell level there may be structural changes that are critical for disease
pathogenesis (Catalano et al., 2009; Papavassiliu et al., 2010).
The developments in human somatic cell reprogramming to induced
pluripotent stem cells (hiPSCs) (Okita et al., 2011; Takahashi et al.,
2007) and targeted differentiation of human pluripotent stem cells
(hPSCs) to cardiomyocytes (CMs) (Burridge et al., 2011; Minami et al.,
2012) have hugely empowered in vitro modelling of hereditary cardiac
disease. Progress has beenmade in establishinghiPSCmodels for certain
arrhythmias such as Long QT syndrome (Matsa et al., 2011; Sala et al.,
2016), however diseases such as BrS present amore variable phenotype
and polygenic background, with the potential added complexity of
endo-epicardial tissue heterogeneities.
Here we aimed to address some of these issues by generating a sim-
ple cardiac model for the action of ajmaline in a BrS context, comprised
of differentiation and electrophysiological analysis of hPSC-cardiac
clusters/CMs from BrS patients and controls. Speciﬁcally we focus on
patients without mutations in the cardiac sodium channel SCN5A,
reﬂecting the predominant clinical population, and how they respond
to ajmaline challenge.
2. Materials and methods
2.1. Consent and ethics
Work with human embryonic stem cells (hESCs) was reviewed and
approved by the UK's Steering Committee For The Stem Cell Bank And
For The Use Of Stem Cell Lines (reference number SCSC13–25). Use of
patient samples following informed consent was approved by the UK's
National Research Ethics Service (13/LO/0224).
2.2. Brugada subject identiﬁcation
BrS subjects were identiﬁed from specialist inherited arrhythmia
clinics, recruiting individuals with a history of BrS and out-of-hospital
cardiac arrest or familymembers of sudden arrhythmic death syndrome
(SADS) victims, who met the diagnostic criteria according to the 2013
inherited arrhythmia consensus document with either a spontaneous
resting type 1 Brugada ECG pattern or positive ajmaline challenge test
on screening (Priori et al., 2014).
2.3. Next generation sequencing (NGS) of patient and control genomic DNA
Followingphenol:chloroformextraction of genomicDNA fromblood
samples, DNA libraries were prepared using the Illumina TruSight
Cardio system (Pua et al., 2016) according to manufacturer's laboratory
protocols, and sequenced on the Illumina NextSeq. Twelve genes in
which variants had been previously reported as causative of BrS were
analysed, together with a further 26 genes reportedly linked to otherinherited arrhythmia syndromes (Table 2). Rare protein-altering vari-
ants were identiﬁed as those occurring at a frequency of ≤0.0001 (1 in
10,000) both in the ExAC database and in a cohort of healthy volunteers
sequenced on the same platform (Lek et al., 2016). For further details
please see Supplementary methods.
2.4. Reprogramming and maintenance of hPSCs
Human dermal ﬁbroblast (HDF) cultures were derived from 4 mm
skin punch biopsies from BrS patient and control individuals following
overnight digestion with collagenase I (Sigma, USA). After two to ﬁve
passages, HDFswere reprogrammedby lentiviral transduction of a poly-
cistronic vector hSTEMCCA (Somers et al., 2010) or nucleofection of
three plasmids containing reprogramming factors (Okita et al., 2011).
Colonies were isolated and expanded clonally in DMEM:F12 medium
containing 20% knock-out serum replacement (Gibco, UK) and
20 ng/ml FGF2 (Peprotech, USA) on mitotically inactivated mouse
embryonic ﬁbroblasts (MEFs), and characterised for pluripotency.
hPSC lines were generally maintained and expanded on MEFs, and
transitioned onto Matrigel in mTeSR for several passages prior to
differentiation.
2.5. Cardiac differentiation of hPSCs
We adapted the protocol published by Burridge and colleagues
(Burridge et al., 2011). hPSCs were enzymatically dissociated with
Accutase (Thermo Fisher, USA) and plated at a density of 1.5–2
× 106/75 cm2 ﬂask pre-coated with Matrigel (Corning, USA) in mTeSR
™1 (Stem Cell Technologies, Canada) + 5 μM Y-27632 (Tocris, UK).
The next day (differentiation day 0–1, “D0”), cells were dissociated
and resuspended at a density of 7 × 104 cells/ml in RPMI-Growth Factor
(RGF) medium (for media formulation please see Supplementary table
S2). Cells were pipetted into conical bottom 96-well plates (100 μl per
well), and centrifuged at 950g for 5 mins to aggregate the cells into
clusters. On D2, medium was exchanged with 100 μl RPMI-Serum (RS)
medium, and on D3 this was again replaced with fresh RS medium but
containing SB431542 (Tocris, UK). On D4, medium was changed for
150 μl RPMI-ITS (RI) medium containing inhibitors KY02111 (Tocris)
and XAV939 (Sigma, UK) (Minami et al., 2012) and clusters were trans-
ferred to round bottom 96-well plates. From D6 and henceforth RI
mediumwithout inhibitors was used tomaintain the clusters, withme-
dium changed every three days. In some experiments, clusters were
transferred and pooled into 6-well plates from D14. For metabolic
enrichment of CMs (Tohyama et al., 2013), cardiac clusters were
maintained in RI comprised of RPMI without glucose (Gibco) and
4 mM sodium lactate (Sigma) between D14–21.
2.6. Multi electrode array (MEA) analysis of hPSC-cardiac clusters
At weeks 6–8 of differentiation, two or three spontaneously
contracting clusters per analysis were loaded onto gelatin or Matrigel-
coated 60PedotMEA200/30iR-AuMEAs (containing 60 gold coated elec-
trodes, 200 μm spaced) (Multi Channel Systems, Germany) in RI medi-
um containing 20% FCS (to promote attachment). After two days,
clusters were analysed using the MEA2100 system with an HS60
headstage, and signals were recorded using MC_Rack software (all
from Multi Channel Systems). Sampling frequency was 10,000 Hz, and
channels with a detectable signal in the range of ±50 μV were selected
and recorded. Basal medium of RPMI containing pen/strep and 5% FCS
+/− drug dose was superfused across clusters at a rate of
~1.5 ml/min, with the headstage and superfused medium maintained
at 37 °C throughout. One minute baseline recordings were taken after
at least 15 mins superfusion of basal medium, and all subsequent
1 min drug dose recordings were taken following 6 mins superfusion.
Drugs tested had stock solutions as follows: ajmaline (Carinopharm
GmBH, Germany) at 15.32 mM in phosphate saline solution (ultrapure
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(Santa Cruz Biotechnology, USA) at 100 mM in DMSO, isoprenaline
(Sigma) at 10 mM in dH2O.
Raw electrode traces were converted using MC_DataTool (Multi
Channel Systems) and analysed using Clampﬁt 10.6 (Molecular Devices,
USA). To compare ﬁeld potentials (FPs), ensemble average signals were
generated from 1 min recordings using CardioMDA software, available
from Pradhapan et al. (Pradhapan et al., 2013). Signals with a baseline
beat rate of at least 25 beats/min (bpm) were averaged using a 90%
correlation factor. Activation-recovery interval was taken as the ﬁeld
potential duration (FPD), and was determined for each ensemble trace
manually based on the interval between the activation and the recovery
peaks, as used previously (Egashira et al., 2012; Harris et al., 2013;
Matsa et al., 2011). FPD values were then corrected (cFPD) using
Bazett's formula (BAZETT, 1997; Sagie et al., 1992). The maximum
negative gradient of the FP activation complex downslope (minimum
velocity, dV/dtmin), used as an indication of depolarisation (Qu and
Vargas, 2015), was determined from ensemble average traces using
Matlab. Statistical analyses were performed using SPSS 23 (IBM, USA)
before or after baseline normalisation of individual electrodes (as
indicated).
2.7. Patch-clamp analysis of hiPSC-CMs
For dissociation of cardiac clusters to single cells, please see Supple-
mentary methods.
Patch clamp recordingswere performedwith an Axopatch 200B am-
pliﬁer (Axon Instruments, USA) at either at room temperature 22±2 °C
(current-clampand INa) or at 36.5±0.5 °C (IKr). Patch-clamp recordings
were performed using ﬁre-polished pipettes with a resistance of 2–4
MΩ pulled from ﬁlamented borosilicated glass capillaries (Harvard Ap-
paratus, 1.5 mmOD× 1.17mm ID). Pipette capacitancewas reduced by
coating the tip with SigmaCote (Sigma). Data were acquired and
analysed by using a Digidata 1440A interface (Axon Instruments) and
pCLAMP software. For sodium currents (INa) all recordings were done
in a low sodium extracellular solution containing (mM): NaCl 25, CsCl
120, CaCl2 1, MgCl2 1, HEPES 5 and Glucose 10 (buffered to pH 7.4
with CsOH). The intracellular solution was (mM): NaCl 5, CsCl 125,
MgATP 2, EGTA 10 and HEPES 20 (buffered to pH 7.2 with CsOH). To
characterize the voltage dependency of the peak INa, cells were held at
−90 mV, and 200 ms steps were applied from −90 mV to +30 mV
in 5 mV increments. The interval between the voltage steps was 3 s.
For IKr and current clamp analysis of action potential (AP), pipette
(intracellular) solution contained (mM): 110 K-D-gluconate, 20 KCl,
10 NaCl, 2 EGTA, 10 HEPES, 1 MgCl2, 0.3 GTP, and 2 MgATP (pH 7.4
with KOH). Extracellular solution (Tyrode's) contained (mM): 135
NaCl, 5.4 KCl, 5 HEPES, 1 MgCl2, 0.33 NaH2PO4, 2 CaCl2 and 10 Glucose
(pH7.4withNaOH). For IKr analysis, the baseline ‘IK’ currentwas record-
ed in the presence of 5 μM nifedipine and 3 μM HMR1556 to block ICaL
and IKs respectively. Two minutes after drug addition, IKr was elicited
by stepped depolarisations from−40 to+30mV for 2 s in 10mV incre-
ments, followed by a repolarising pulse back to−40mV for 2 s (tomea-
sure IKr tail currents). Ajmaline (100 μM) (with nifedipine 5 μM and
HMR1556 3 μM)was then perfused for 2 min and a second I/V protocol
was run. After the second I/V protocol ajmaline perfusion was stopped
and the recovery of the IKr current monitored by successive I/V proto-
cols. If IKr tail current returned this was then blocked by the addition
of dofetilide 1 μM (an IKr speciﬁc blocker) (with nifedipine 5 μM and
HMR1556 3 μM) for 2 min and a ﬁnal I/V protocol recorded. Series
resistance was compensated by ~70% using the ampliﬁer circuitry.
Current-voltage relationships were determined by normalising the
maximal current densities at the end of each pulse potential to cell
capacitance (pA/pF). Peak tail current density (PTCD) was determined
by normalising the maximal current densities of the peak tail currents
in response to each pulse potential to cell capacitance (pA/pF). For
current-clamp analysis, once the whole-cell conﬁguration had beenachieved, APs were recorded in the current-clamp mode. For cells that
were spontaneously ﬁring we ﬁrst recorded their activity and then ap-
plied a trigger (500pA-1.8 nA depending on cell size and response) at
a frequency of 1 Hz. For cells that were quiescent we applied a trigger
(500pA-1.8 nA depending on cell size and response) at a frequency of
1 Hz. Cells with a resting membrane potential (RMP) of above
−30 mV were not included in the analysis because they were consid-
ered to be either too immature or non-cardiac. APs were Liquid Junction
Potential (LJP) corrected (LJPc). The LJPc (13.4mV)was calculated using
the Clampex Junction Potential Calculator. Experiments were analysed
using Clampﬁt, and Origin, and data statistically compared using SPSS
23.
APmorphologies were categorised based on the ratio of AP duration
(APD)90/50, as described and used previously (Matsa et al., 2011). APs
with a plateau phase as distinguished by a ratio ≤ 1.4 were considered
ventricular, those with ≥1.7 atrial, and 1.4 to 1.7 nodal-like.
2.8. Reverse transcription PCR (RT-PCR)
The relative expression of targets was determined by qRT-PCR using
the 2−ΔCt method (Schmittgen and Livak, 2008), normalised to GAPDH
as the housekeeping gene. For further details please see Supplementary
methods.
2.9. Immunoﬂuorescence microscopy and ﬂow cytometry
For details of protocols and reagents please see Supplementary
methods.
3. Results
3.1. Generating and differentiating hiPSC cardiac clusters
In order to establish a simple in vitromodel to investigate the effects
of ajmaline, we began by generating a control hiPSC line from a
consenting adult male without a BrS phenotype, designated HS1M.
HDFs were reprogrammed using a polycistronic lentiviral vector con-
taining Yamanaka factors (Somers et al., 2010),with several colonies in-
dividually isolated in the ﬁrst passage and clonally expanded. Tra-1-60
live cell staining was used to screen colonies at passage 2 (data not
shown). Positive clonal lines were expanded and screened for consis-
tent cellular morphology, expression of pluripotency-associated
markers, normal karyotype, and embryoid body (EB) differentiation to
all three germ layers (Fig. 1A–C). One line was selected for differentia-
tion experiments, designated iPS-HS1M.
To generate cardiac material readily usable for electrophysiological
analysis, we adapted features of the EB/cardiac cluster protocol pub-
lished by Burridge and colleagues (Burridge et al., 2011), additionally
employing the Activin/Nodal receptor inhibitor SB431542 on day 3,
followed by the two canonical WNT inhibitors KY02111 and XAV939
from the report by Minami (Minami et al., 2012) on days 4–6
(Fig. 1D). Cluster morphology was consistent, with beating observed
from day eight onwards (Movie 1). Flow cytometry analysis following
dissociation of clusters at day 21 showed a cardiac Troponin T
(TNNT2) expressing population of 52.2% ± 12.2 (n = 4) (Fig. 1E).
CMs were observed by immunoﬂuorescence microscopy, with sarco-
meric structures evident by TNNT2 staining, aswell as nuclear co-staining
of the pan-cardiac marker NKX2-5 (Fig. 1F).
3.2. Ajmaline reduces activation and lengthens activation-recovery interval
of hiPSC cardiac clusters
In order to validate the hiPSC cardiac clusters and determine the
effects of ion channel inhibitors, we loaded iPS-HS1M cardiac clusters
onto MEAs after six to eight weeks of differentiation, to measure
the FP of spontaneous contraction. Cardiac clusters were responsive to
Fig. 1. Reprogramming of hiPSCs and differentiation to cardiac clusters. A) Immunocytochemistry of pluripotency associated factors in iPS-HS1M hiPSCs following reprogramming from
HDFs. Bar = 100 μm. B) Immunocytochemistry of lineage markers of mesoderm (ACTA2), neurectoderm (TUBB3) and endoderm (SOX17) plus DAPI staining (blue) following non-
directed EB differentiation and outgrowth. Bar = 100 μm. C) G banding of iPS-HS1M, indicating a normal karyotype following reprogramming. D) Schematic with phase contrast images
inset of hiPSC differentiation to cardiac clusters. For media formulations see Supplementary table S2. Bar = 500 μm. E) Flow cytometry analysis of TNNT2 expression in iPS-HS1M at
differentiation day 21, with IgG isotype control inset. F) Immunocytochemistry of NKX2-5 and TNNT2 plus DAPI at day 28 of differentiation following partial dissociation of iPS-HS1M
cardiac clusters. Bar = 100 μm.
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ing 500 nM isoprenaline superfusion (Fig. 2A). Drugs were adminis-
tered via superfused medium in increasing doses for 6 mins each
followed by 1 min recordings (Fig. 2B), sufﬁcient that each dose had a
stable effect on clusters (Supplementary Fig. S1A\\B). To generate
representative data sets, recordings of drug dose effects vs baseline
were taken from multiple clusters across at least eight electrodes,
from three or more separate MEA analyses and where possible from
several independent differentiation experiments.
Superfusion of basal medium alone over successive 6 min intervals
had no effect on cFPD, however treatment with increasing doses of
ajmaline consistently lengthened cFPD, signiﬁcantly increasing the acti-
vation-recovery interval by 1.46 fold at 100 μM (Fig. 2C–D). We also
enriched our clusters for CM content using sodium lactate (Tohyamaet al., 2013) and observed near identical effects of ajmaline on the acti-
vation-recovery interval (Supplementary Fig. S1C–D). In comparison
with ajmaline, the Nav1.5 channel inhibitor mexiletine caused no ob-
servable effect on cFPD (Fig. 2C–D) until 1mM, atwhich point complete
cessation of contraction occurred (data not shown). We also tested
dofetilide, the potent rapid delayed rectifying potassium current (IKr)
blocker, and found that it had a dramatic effect on spontaneous contrac-
tion of clusters, causing the cFPD to lengthen at doses several orders of
magnitude lower than ajmaline (Fig. 2C–D). Dofetilide also appeared
to cause an increased beat rate in clusters, whereas again mexiletine
had no observable effect (until cessation at 1 mM) and ajmaline tended
to slow cluster beating at 100 μM (Supplementary Fig. S1E). To deter-
mine what effects these drugs had on cluster activation, we compared
the downslope gradient of the FP activation complexes at baseline and
Fig. 2. Effects of ion channel inhibitors on ﬁeld potential (FP) of hiPSC cardiac clusters. A) Raw FP signal from a single MEA electrode, showing the effect following 6 mins superfusion of
500 nM isoprenaline (black arrow). B) Schematic of MEA protocol, with phase contrast image inset of cardiac clusters loaded onto an MEA. Bar = 500 μm. C) Representative ensemble FP
signals at individual electrodes, showing effect of increasing doses of ajmaline, mexiletine or dofetilide on iPS-HS1M clusters. Arrow heads indicate examples for time points of activation
and recovery peaks, to calculate cFPD. Grey dashed line shows 0 μV. D–E) Mean iPS-HS1M cluster activation-recovery interval over increasing drug doses (D), or activation complex
downslope gradient dV/dt(minimum) at highest drug dose (E), showing effect of ajmaline (n ≥ 9), mexiletine (n ≥ 9) and dofetilide (n ≥ 4, some clusters ceased beating or were too
inconsistent to generate ensemble averages at higher doses) normalised to baseline, error bars show ± s.e.m. One way ANOVA followed by Tukey HSD (D) or paired t-test (E), ** = p
≤ 0.01 or * = p ≤ 0.05 respectively vs baseline before normalisation.
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reduced the gradient of activation, whereas mexiletine had no clear ef-
fect, and dofetilide appeared to greatly reduce the activation complexes
(although also causing inconsistent beating or cessation at the highest
dose) (Fig. 1C, E). These data suggest that ajmaline may affect
depolarisation as well as cause lengthening of cFPD similarly to
dofetilide via inhibition of repolarising currents such as IKr in spontane-
ously contracting hiPSC cardiac clusters.
3.3. Ajmaline blocks INa and IKr in hiPSC-CMs
Since ajmaline at higher doses had such a clear and consistent effect
on hiPSC cardiac cluster activation-recovery interval, we sought toidentify whether ajmaline is able to inhibit IKr in hiPSC-CMs, as well as
conﬁrm it can inhibit INa on which its clinical diagnostic use is based
(Sarquella-Brugada et al., 2015). Ajmaline has been detected in subjects
showing idioventricular rhythm at plasma concentrations of 9.1–46.17
μM (Padrini et al., 1993), so we chose the higher dose from our MEA
analysis of 100 μM to investigate isolated iPS-HS1M CMs by patch
clamping.
Following administration of ajmaline, we observed marked inhibi-
tion of INa in hiPSC-CMs compared to baseline control (Fig. 3A, B), and
this inhibition was partially recovered after washout: pA/pF control =
−110 ± 18.7, ajmaline = −15.4 ± 4.4, washout = −55 ± 11.6.
When isolating outward potassium currents, the perfusion of ajmaline
at 100 μM also resulted in an approximate 50% reduction in current
Fig. 3.Ajmaline blocks both INa and IKr in hiPSC-CMs. A) Representative INa traces and current density (pA/pF) under control conditions and after application of ajmaline (100 μM), n= 15
cells. B) Representative traces showing the effect of application of ajmaline (100 μM) on IKr tail currents. The voltage protocol and scale are inset. C) Digital subtraction of the current
blocked by ajmaline. D) In some cells the IKr tail current partially recovered after removal (washout) of ajmaline (indicated by arrow) and this could then be blocked by the addition of
the IKr speciﬁc blocker dofetilide (1 mM). E) Current density before and after ajmaline application. F) Peak-tail current density (PTCD) before and after ajmaline application. * = p ≤
0.05 (paired t-test) compared to baseline value before ajmaline addition, n = 8 cells. Data displayed as mean ± s.e.m.
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pared to baseline control, which could be partially recovered after
washout (Fig. 3C–F). The complete loss of tail current indicates that
ajmaline acts to completely block IKr at 100 μM. These data therefore
show that ajmaline inhibits both sodium and potassium currents in
hiPSC-CMs, and support our observation that ajmaline lengthens the ac-
tivation-recovery interval of hiPSC cardiac clusters by inhibiting IKr.
3.4. BrS patient selection and genotyping
Having established that MEA analysis could reveal the actions of
ajmaline on hiPSC cardiac clusters, we sought to create a BrS hiPSC plat-
form that would be representative of BrS genetic aetiology. Consenting
patients were selected from a cohort afﬁliated with the former UCLH
Heart Hospital, UK. Patientswere screened based on a strongBrS pheno-
type, and absence of putative pathogenic SCN5Amutations. Fitting these
criteria were three male patients (mean age 42.4 ± 12.9 years), desig-
nated BrS patient 3 male (BR1-P3M), BR1-P5M and BR1-P6M. Patients
exhibited a BrS ECG pattern in line with HRS/EHRA/APHRS consensusguidelines (Priori et al., 2014) in ≥1 precordial lead either spontaneous-
ly or following ajmaline treatment, and in some cases had suffered VF
events (Fig. 4A–C, Table 1). NGS of BrS patients and our control HS1M
using the Illumina TruSight Cardio panel (Pua et al., 2016) did not reveal
any rare protein altering variants in BrS genes as deﬁned by ≤0.0001 fre-
quency in the ExAC database (see Methods). We note a variant in PKP2
(ExAC 0.00012) in BR1-P3M that has previously been linked to BrS, but
has also been repeatedly observed at low frequency in the population,
and is considered of unknown signiﬁcance or likely benign. Otherwise,
NGS data indicated that our individuals were absent of rare protein-al-
tering and likely pathogenic variants in SCN5A, other BrS associated
genes, or inherited arrhythmia-related targets (see Table 2).
3.5. BrS patient and control hPSC cardiac differentiation and AP
characterisation
HDFs from our three patients were reprogrammed to hiPSCs using ei-
ther the lentiviral vector as before or by nucleofection of reprogramming
factors (Okita et al., 2011). Colonieswere selected, clonally expanded, and
Fig. 4. BrS patient ECGs. A–C) ECGs of patients BR1-P3M (A), BR1-P5M (B) and BR1-P6M
(C), with an abnormal ST segment and T wave evident in precordial lead 1 (V1) and/or
V2, either spontaneously (B), or after administering 1 mg/kg ajmaline (A, C).
239D.C. Miller et al. / Stem Cell Research 25 (2017) 233–244characterised as before (Supplementary Fig. S2), from which four lines
were selected: iBR1-P5M-L1 and -L9, iBR1-P6M-L1, and iBR1-P3M-N2
(−L[number] or –N[number] denoting lentiviral or nucleofection clone
number).
To compare BrS patient and control hPSC lines we ﬁrst used our
directed differentiation protocol to generate cardiac clusters. The
sequential use of small molecule inhibitors generated consistently
high percentages of spontaneously contracting clusters across all lines,
88–95% at day 14, with a range of 37–71% range of TNNT2+ cellsdetected at day 21 (Supplementary Fig. S3B). To further validate cardiac
differentiation, analysis of marker transcripts by qRT-PCR was per-
formed on iPS-HS1M and iBR1-P5M-L1. Temporal induction of cardiac
progenitor markers GFRA2 and ISL1 (Bu et al., 2009; Ishida et al., 2016)
and CM markers TNNT2 and MYH7 was very similar over the ﬁrst
21 days between the two cell lines (Fig. 5A). At day 50, clusters showed
comparably high transcript proﬁles ofMYH7 and the sodium and potas-
sium ion channel subunits SCN5A and KCNH2 (Fig. 5B). These data do
not reveal any gross difference in cardiac differentiation capacity
between the BrS patient and control hPSCs using the cardiac cluster
protocol.
To assess the composition of cardiac clusters andwhether theremay
be any obvious intrinsic difference between BrS patient and control
CMs, we performed current clamp analysis of single cells dissociated
from clusters after six to eight weeks of differentiation, to determine
their AP types and parameters. We decided to focus on only one patient
and a control, given a recent publication by Veerman and colleagues
ﬁnding almost no differences following comprehensive characterisation
of membrane currents and APs in hiPSC-CMs from SCN5A mutation-
negative BrS patients (Veerman et al., 2016). Patient BR1-P5M was
chosen given his severe phenotype, having suffered spontaneous VF
events leading to cardiac arrest during adolescence (Table 1). The AP
morphologies, categorised based on APD90/50 ratios as used previously
(Matsa et al., 2011) (see Materials and methods), suggested a similar
range/composition of CM types from control and BrS clusters,with atrial
or ventricular-like APs prevalent as well as a few APs with nodal/pace-
maker-like morphology (Fig. 5C). The APDs were quite variable across
CMs, with mean APD90 measurements of 183.0 ± 17.9 and 125.5 ±
12.4 ms for control and patient CMs respectively (Fig. 5D, n = 21 and
17 from two independent parallel differentiation experiments). RMP
of iBR1-P5M-L1 CMs was slightly higher (Fig. 5E), however we saw no
differences in AP amplitude (Fig. 5F) or AP upstroke velocity (Fig. 5G)
between the two lines. These trends were also maintained when re-
garding only the ventricular-like CMs of the control and patient lines
(n= 7 and 9). These data therefore indicated that although BrS patient
and control hiPSC clusters were of mixed CM composition, they were
consistent and comparable across most CM parameters.
3.6. Ajmaline treatment of BrS patient and control hPSC cardiac clusters
Since both we and others (Veerman et al., 2016) could identify few
clear cell-intrinsic differences between hiPSC-CMs from controls and
BrS patients absent of pathogenic SCN5A mutations, we decided to
apply our multi-cellular cluster model to identify by MEA whether
ajmaline could elicit a different response in activation-recovery interval
between patients and controls. Cardiac clusters were loaded on MEAs
and cFPD determined as before following increasing doses of ajmaline.
Baseline cFPD across the different lines had a range of 281 to 395 ms,
and although the patient lines P3M-N2 and P6M-L1 had signiﬁcantly
longer cFPD than HUES7 and/or P5M-L9, there was no signiﬁcant differ-
ence found between the BrS patients or the control iPS-HS1M line
(Supplementary table S1 and Supplementary Fig. S3C). Upon ajmaline
addition, as observed with iPS-HS1M, all lines showed a steady increase
in activation-recovery interval, with the cFPD becoming signiﬁcantly
longer at 100 μM and in some lines at 10 μM compared to baseline
(Fig. 6). Complete cessation of spontaneous contraction occurred at
1 mM ajmaline (data not shown). Comparing the relative cFPD at 10
μM and 100 μM ajmaline across the patients and controls, we found
no signiﬁcant differences between any of the hPSC lines (one way
ANOVA, p= 0.131 and 0.399 respectively). Similarly, upon comparison
of the effect on cardiac cluster activation, no difference was found be-
tween the lines in the relative reduction of activation following the
highest dose of ajmaline (one way ANOVA, p = 0.244, Supplementary
Fig. S3D). Altogether, these data indicate that ajmaline consistently
lengthens the activation-recovery interval as well as slightly reducing
activation in hPSC cardiac clusters, however hPSC clusters from BrS
Table 1
Subjects used in study.
Individual
designation
Disease
state
Age Clinical notes Arrhythmia related rare variants detected by NGS
HS1M – 39 – –
BR1-P3M Br1 68 Ajm inducible elevation + coved S-T leading to VF, occasional spont. PKP2 – nsSNP, c.302GNA, p.R101H, VUS
(ExAC 0.00012)
BR1-P5M Br1 28 VF arrest 16yo, spont. J-point elevation, not-quite-coved S-T, father similar ECG –
BR1-P6M Br1 30 Ajm inducible type I, occasional spont. –
Abbreviations: Br1 – Brugada syndrome type I ECG, Ajm – ajmaline, spont. – spontaneous, VF – ventricular ﬁbrillation, nsSNP – non-synonymous single nucleotide polymorphism, c. –DNA
coding sequence, p.- protein sequence, VUS – variant of unknown signiﬁcance.
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ther more nor less sensitive to these effects compared to control.
4. Discussion
In this study we describe the action of ajmaline in a simple hiPSC
model of human cardiac electrophysiology. Interestingly, in addition
to inhibition of INa, ajmaline signiﬁcantly altered repolarisation through
block of IKr in hiPSC-CMs, consistently lengthening the activation-recov-
ery interval of cardiac clusters, emphasising that the action of ajmaline
is broader than previously thought. Furthermore, we have generated
hiPSCs from a number of patients with BrS. We selected patients with
no genetic evidence of a sodium channel or other ion channel defect.
We showed that there were few differences in electrophysiology be-
tween BrS patient and control hPSC-CMs or clusters, as assessed by AP
morphology andMEA recordings in the absence or presence of ajmaline.
We challenged hiPSC-CMs with the drug ajmaline to elucidate its
mode of action and parallel its diagnostic application in BrS. Plasma con-
centrations of 9.1–46.17 μM have been detected in subjects showing
idioventricular rhythm (Padrini et al., 1993), hence our dose range
was appropriate to study the drug's effects in the context of a disease
model. We saw a prominent and consistent lengthening of cFPD in all
cell lines including control and BrS patient cells. This did not occur
with another class I anti-arrhythmic and sodium channel blocking
drug, mexiletine, and more closely resembled the IKr blocker dofetilide.
Furthermore, using patch clampingwe isolated INa and IKr in hiPSC-CMs
and showed that ajmaline blocked both currents. It is known that in ad-
dition to blocking INa, ajmaline can block Ito, ICaL and IKr, though this has
been shown only in heterologous expressions systems or animal cells
(Bébarová et al., 2005; Fischer et al., 2013; Kiesecker et al., 2004). How-
ever, this complex pharmacology is under appreciated and we demon-
strate the ability of ajmaline to block IKr for the ﬁrst time in a hiPSC-
CM assay system. Interestingly, ajmaline and dofetilide both inhibited
FP activation of cardiac clusters, and the latter also dramatically in-
creased the beat rate, despite being a well characterised highly speciﬁc
IKr blocker (Roukoz and Saliba, 2007). Both these effects may be caused
indirectly due to the role IKr plays in repolarisation of hPSC-CMs in the
context of a 3D cluster: hPSC-CMs are known to lack robust expression
of IK1, hence IKr is required to set the resting membrane potential (Doss
et al., 2012). When IKr is blocked a more depolarised diastolic potential
results in a reduced current upon depolarisation, and CMs that aremore
readily triggered to depolarise are then also likely to beat faster (Qu and
Vargas, 2015). Our data closely recapitulate the observations by Qu and
Vargas regarding dofetilide, suggesting that FP recordings can be useful
for determining drug effects on repolarisation, speciﬁcally IKr, but may
be limited in their ability to faithfully report direct effects on
depolarisation in hPSC-CMs, particularly those lacking IK1.Table 2
Gene list of general arrhythmia related targets within the TruSight Cardio panel (Pua et al., 201
Reported BrS genes SCN5A, CACNA1C, CACNA2D1, CACNB2, GPD1L, HCN4,
Other inherited
arrhythmia-related genes
KCNH2, KCNQ1, RYR2, ABCC9, AKAP9, ANK2, CALM1, C
MYH6, NKX2-5, NPPA, PKP2, SCN4B, SNTA1, TRDNSeveral recent studies have begun to address disease modelling of
BrS using hPSCs. However, there has been a preferential focus on single
cells and cases with SCN5A mutations. Liang and colleagues examined
two patients, one with a missense mutation in a region important for
voltage sensing and the other a base pair deletion leading to a prema-
ture stop (Liang et al., 2016). CMs showed reduced sodium current, re-
duced upstroke velocity of APs, triggered activity and abnormal Ca2+
transients. The abnormal cellular behaviour was corrected by gene
editing of the mutation. In a second recent study, Kosmidis and col-
leagues studied two nonsense mutations in SCN5A and also found re-
duced sodium currents and slower AP upstroke velocity (Kosmidis et
al., 2016). Interestingly, readthrough therapy restored function to the
channels in HEK293 cells but not hiPSC-CMs. In our study, we instead
focussed on the common clinical scenario of SCN5A (and other ion
channel) mutation-negative BrS patients to test whether electrophysio-
logical differences could be revealed in this group. We began with AP
measurements in onepatient andone control as a broad assay for intrin-
sic cellular differences. Speciﬁcally, we saw no evidence for slowing of
AP upstroke velocity, suggesting that the function of INa is not promi-
nently affected. The slightly reduced APD of our BrS patient was similar
to that observed in the report by Veerman et al. (Veerman et al., 2016).
Our AP data agree with the ﬁndings of their detailed electrophysiologi-
cal study of CMs from SCN5Amutation-negative BrS patients. This raises
several key points, especially where models aim to elicit potentially
modest differences at the single cell level, from a disease with complex
aetiology and subtle or unclear pathophysiology. It is known that hPSC-
CMs are more closely aligned in electrophysiological phenotype to foe-
tal cells (Veerman et al., 2015). We cannot exclude the possibility that
some differences may manifest themselves if CMs are matured to a
more adult or right ventricular outﬂow tract speciﬁcation.
We had aimed to determinewhether the effect of ajmaline onwhole
cardiac clusters from BrS patients could provide an additional platform
for investigation, especially given the drug's effects on our patients'
ECGs and consistency in control hiPSC clusters. A multicellular system
to model diseases such as BrS could provide much insight into
arrhythmogenesis. Although we saw no differences with our simple
cluster based system, a phenotype may be revealed in more precisely
engineered cardiac microtissues, perhaps including co-culture with ﬁ-
broblasts or endothelial cells, that more closely recapitulate the native
tissue composition of the heart (Pellman et al., 2016), examples of
which are rapidly developing (Giacomelli et al., 2017; Schaaf et al.,
2016; Thavandiran et al., 2013; Tiburcy et al., 2017). Furthermore, this
could be enhanced via selection for speciﬁc populations of CMs for ex-
ample expressing a ventricular marker increasing the ﬁdelity and po-
tentially the sensitivity of such a model for diseases such as BrS.
The failure to ﬁnd cellular electrophysiological abnormalities in this
study and others supports the hypothesis that in a signiﬁcant number of6) assessed in BrS patient and control individuals by NGS.
KCND3, KCNE3, KCNJ8, RANGRF, SCN1B, SCN3B
ASQ2, CAV3, DSC2, EMD, GJA5, JPH2, KCNA5, KCNE1, KCNE2, KCNJ2, KCNJ5, LMNA,
Fig. 5. Comparison of BrS patient and control hiPSC-CM differentiation and APs. A–B) qRT-PCR analysis ofmarker expression during cardiac cluster differentiation of control iPS-HS1M and
BrS patient iBR1-P5M-L1 lines. Data displayed from n = 3 (A) or n = 4 (B) independent differentiation experiments ± s.e.m. C–G) APs recorded from isolated iPS-HS1M (n= 21) and
iBR1-P5M-L1 CMs (n = 17) at weeks 6–8 of differentiation. C) Representative traces and proportion of AP types (assigned as described in Methods). The arrow heads indicate that the
AP was triggered (at 1 Hz). The grey dashed line indicates 0 mV. D–G) Collated AP data displaying the range of APD90 values (D), Resting Membrane Potential (RMP) (E), AP
amplitude (F) and Upstroke Velocity (G). Data displayed as mean ± s.e.m. * = p ≤ 0.05 (independent t-test) vs control line iPS-HS1M.
241D.C. Miller et al. / Stem Cell Research 25 (2017) 233–244BrS patients there may not be a strong genetically inherited substrate
arising from ion channel defects. There are two major hypotheses for
themechanism of disease which are not necessarily mutually exclusive.
The characteristic ECG changes occur because there is either delayed
depolarisation or early repolarisation in different regions of the right
ventricular outﬂow tract (Antzelevitch, 2007; Coronel et al., 2005;
Lambiase et al., 2009; Morita et al., 2008). These hypotheses are sup-
ported by the effects of ﬁbrosis, tissue architectural changes or gap junc-
tion disruption to promote conduction delays, or cellular uncoupling
effects in the myocardium which enable subtle differences in epi- and
endocardial repolarisation behaviour to be dissociated and expressedon the surface ECG (Agullo-Pascual et al., 2014). The processes
determining these could be genetic, environmental including age (BrS
predominantly manifests in middle age) and the effects of previous
myocarditis. It is being increasingly recognised that the epicardium of
Brugada patients exhibits ﬁbrotic changes and discontinuous conduc-
tion (Nademanee et al., 2015). This has led to an approach to ablate
the tissue which would homogenise the substrate to abolish the ECG
pattern and minimise the opportunity for local re-entry and wavebreak
to develop (Brugada et al., 2015; Nademanee et al., 2011). Our data here
support the contention that tissue architectural changes conspire to
produce the Brugada phenotype independent of ion channel mutations.
Fig. 6. Effect of ajmaline on FPof BrS patient and control hPSC cardiac clusters. A) Representative ensemble FP signals at individual electrodes, showing effect of increasing doses of ajmaline
on cardiac clusters from different hPSC lines. Grey dashed line shows 0 μV. B) Mean activation-recovery interval of clusters from different hPSC lines with increasing doses of ajmaline,
calculated from cFPD relative to baseline reading. Data averaged from n ≥ 8 electrodes from n ≥ 3 MEA assays (see Supplementary table S1). One way ANOVA followed by Tukey HSD
performed before normalisation, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001 vs. baseline.
242 D.C. Miller et al. / Stem Cell Research 25 (2017) 233–244The use of ajmaline is proposed to magnify conduction delay, but our
hiPSC data demonstrate that it is also possible that it may have differen-
tial effects on repolarisation.
5. Conclusions
In conclusion, we show using a simple hiPSC cardiac assay system
that ajmaline exhibits previously undescribed effects on activation-re-
covery interval via IKr block, in addition to the inhibition of INa. However,
the system could not reveal electrophysiological differences between
hPSCs from controls and BrS patients absent of pathogenic SCN5Amuta-
tions, even after challengewith ajmaline, highlighting future challenges
inmodelling the complex aetiology and pathophysiology of the disease.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.scr.2017.11.003.
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